Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.34 |
| ▸ | CTSL | P07711 | 2/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3596637 | 0.80 | AAK1 (0.36) | CTSSCTSKAAK1CTSLHDAC4 | |
| SCHEMBL5629890 | 0.80 | AAK1 (0.36) | CTSSCTSKAAK1CTSLHDAC4 | |
| SCHEMBL5629894 | 0.80 | AAK1 (0.36) | CTSSCTSKAAK1CTSLHDAC4 | |
| SCHEMBL647488 | 0.75 | AAK1 (0.37) | CTSSCTSKAAK1CTSLHDAC4 | |
| SCHEMBL649703 | 0.74 | AAK1 (0.36) | CTSSCTSKAAK1CTSLHDAC4 | |
| SCHEMBL6203221 | 0.74 | AAK1 (0.36) | CTSSCTSKAAK1CTSLHDAC4 | |
| SCHEMBL6203226 | 0.74 | AAK1 (0.36) | CTSSCTSKAAK1CTSLHDAC4 | |
| SCHEMBL464205 | 0.68 | AAK1 (0.47) | CTSSCTSKAAK1CTSLHDAC4 | |
| SCHEMBL6820204 | 0.68 | AAK1 (0.47) | CTSSCTSKAAK1CTSLHDAC4 | |
| SCHEMBL3372810 | 0.68 | AAK1 (0.47) | CTSSCTSKAAK1CTSLHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119664-B2 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2012-02-21 | — | — | US | disclosed |
| US-20070238753-A1 | Pharmaceutical Compositions as Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV) | MADAR DAVID J | 2007-10-11 | — | — | US | disclosed |
| US-7262207-B2 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2007-08-28 | — | — | US | disclosed |
| US-20040259843-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238753-A1 | Pharmaceutical Compositions as Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | CTSS 821/4885CTSK 808/4885AAK1 2086/4885 |
| US-20040259843-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | CTSS 870/4885CTSK 832/4885AAK1 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.